CN101312715B - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN101312715B
CN101312715B CN200680043657XA CN200680043657A CN101312715B CN 101312715 B CN101312715 B CN 101312715B CN 200680043657X A CN200680043657X A CN 200680043657XA CN 200680043657 A CN200680043657 A CN 200680043657A CN 101312715 B CN101312715 B CN 101312715B
Authority
CN
China
Prior art keywords
azd2171
filler
tablet
pharmaceutical composition
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680043657XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101312715A (zh
Inventor
D·B·B·辛普森
J·K·卡希尔
S·里彻
D·J·库姆伯巴特克
D·J·霍尔特
E·A·斯温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101312715A publication Critical patent/CN101312715A/zh
Application granted granted Critical
Publication of CN101312715B publication Critical patent/CN101312715B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200680043657XA 2005-11-23 2006-11-21 药物组合物 Expired - Fee Related CN101312715B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0523810.0A GB0523810D0 (en) 2005-11-23 2005-11-23 Pharmaceutical compositions
GB0523810.0 2005-11-23
PCT/GB2006/004320 WO2007060402A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011102142130A Division CN102327267A (zh) 2005-11-23 2006-11-21 药物组合物

Publications (2)

Publication Number Publication Date
CN101312715A CN101312715A (zh) 2008-11-26
CN101312715B true CN101312715B (zh) 2011-12-14

Family

ID=35601030

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200680043657XA Expired - Fee Related CN101312715B (zh) 2005-11-23 2006-11-21 药物组合物
CN2011102142130A Pending CN102327267A (zh) 2005-11-23 2006-11-21 药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011102142130A Pending CN102327267A (zh) 2005-11-23 2006-11-21 药物组合物

Country Status (17)

Country Link
US (1) US20090028943A1 (cg-RX-API-DMAC7.html)
EP (2) EP1954247A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009516726A (cg-RX-API-DMAC7.html)
KR (1) KR20080070056A (cg-RX-API-DMAC7.html)
CN (2) CN101312715B (cg-RX-API-DMAC7.html)
AR (1) AR057928A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006318946A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0618906A2 (cg-RX-API-DMAC7.html)
CA (1) CA2628917A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP088555A (cg-RX-API-DMAC7.html)
GB (1) GB0523810D0 (cg-RX-API-DMAC7.html)
NO (1) NO20082097L (cg-RX-API-DMAC7.html)
RU (1) RU2008125197A (cg-RX-API-DMAC7.html)
TW (1) TW200735875A (cg-RX-API-DMAC7.html)
UY (1) UY29952A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007060402A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200804103B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
EP2299982B1 (de) * 2008-06-20 2018-04-04 Merck Patent GmbH Direkt verpressbare und schnell zerfallende tablettenmatirx
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
WO2020243021A2 (en) 2019-05-24 2020-12-03 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
PE20221838A1 (es) * 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
CN115400136B (zh) * 2022-07-22 2023-10-03 江苏亚邦爱普森药业有限公司 一种克拉霉素固体制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096224A2 (en) * 2003-04-29 2004-11-11 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
WO2005061488A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
EP1175899B1 (fr) * 2000-07-27 2007-08-29 Roquette FrÀ¨res Granules à base d'amidon et de lactose
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
CA2363528A1 (en) * 2001-11-19 2003-05-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immediate release tablet containing naproxen sodium
EP2292615A1 (en) * 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
CA2488499C (en) * 2002-06-10 2013-03-19 Elan Pharma International Ltd. Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096224A2 (en) * 2003-04-29 2004-11-11 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
WO2005061488A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

Also Published As

Publication number Publication date
CA2628917A1 (en) 2007-05-31
UY29952A1 (es) 2007-06-29
GB0523810D0 (en) 2006-01-04
ECSP088555A (es) 2008-07-30
ZA200804103B (en) 2009-10-28
NO20082097L (no) 2008-08-18
CN101312715A (zh) 2008-11-26
AR057928A1 (es) 2007-12-26
EP2283828A1 (en) 2011-02-16
CN102327267A (zh) 2012-01-25
AU2006318946A1 (en) 2007-05-31
JP2009516726A (ja) 2009-04-23
RU2008125197A (ru) 2009-12-27
EP1954247A1 (en) 2008-08-13
WO2007060402A1 (en) 2007-05-31
TW200735875A (en) 2007-10-01
US20090028943A1 (en) 2009-01-29
BRPI0618906A2 (pt) 2013-01-08
KR20080070056A (ko) 2008-07-29

Similar Documents

Publication Publication Date Title
CN101312715A (zh) 药物组合物
EP2209501A2 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
AU2026202283A1 (en) Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
TW202206074A (zh) 藥物配製物
CN101031303B (zh) 包含zd6474的药物组合物
WO2018153379A1 (zh) 一种2-氨基嘧啶类化合物的药用组合物及其制备方法
WO2020038434A1 (zh) 一种2-氨基嘧啶类化合物的药用组合物
HK1099220B (en) Pharmaceutical compositions comprising zd6474

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111214

Termination date: 20121121